A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting risperidone

References

• Hiemke C, Baumann P, Bergemann N, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry. 2011;44(6):195–235.
   Web of Science ®Google Scholar
• Doan J, Zakrzewski-Jakubiak H, Roy J, et al. Prevalence and risk of potential cytochrome P450-mediated drug-drug interactions in older hospitalized patients with polypharmacy. Ann Pharmacother. 2013;47(3):324–332.
   PubMed Web of Science ®Google Scholar
• Bottino CM, Barcelos-Ferreira R, Ribeiz SR. Treatment of depression in older adults. Curr Psychiatry Rep. 2012;14(4):289–297.
   PubMed Web of Science ®Google Scholar
• Gallego JA, Bonetti J, Zhang J, et al. Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schiz Res. 2012;138(1):18–28.
   PubMed Web of Science ®Google Scholar
• Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951–962.
   PubMed Web of Science ®Google Scholar
• Maher AR, Maglione M, Bagley S, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA. 2011;306(12):1359–1369.
   PubMed Web of Science ®Google Scholar
• de Leon J, Sandson NB, Cozza KL. A preliminary attempt to personalize risperidone dosing using drug-drug interactions and genetics: part I. Psychosomatics. 2008;49(3):258–270.
   PubMed Web of Science ®Google Scholar
• de Leon J, Wynn G, Sandson NB. The pharmacokinetics of paliperidone versus risperidone. Psychosomatics. 2010;51(1):80–88.
   PubMed Web of Science ®Google Scholar
• Lako IM, van Den Heuvel ER, Knegtering H, et al. Estimating dopamine D2 receptor occupancy for doses of 8 antipsychotics: a meta-analysis. J Clin Psychopharmacol. 2013;33(5):675–681.
   PubMed Web of Science ®Google Scholar
• Yilmaz Z, Zai CC, Hwang R, et al. Antipsychotics, dopamine D2 receptor occupancy and clinical improvement in schizophrenia: a meta-analysis. Schizophr Res. 2012;140(1–3):214–220.
   PubMed Web of Science ®Google Scholar
• Uchida H, Takeuchi H, Graff-Guerrero A, et al. Dopamine D2 receptor occupancy and clinical effects: a systematic review and pooled analysis. J Clin Psychopharmacol. 2011;31(4):497–502.
   PubMed Web of Science ®Google Scholar
• Nakajima S, Uchida H, Bies RR, et al. Dopamine D2/3 receptor occupancy following dose reduction is predictable with minimal plasma antipsychotic concentrations: an open-label clinical trial. Schizophr Bull. 2016;42(1):212–219.
   PubMed Web of Science ®Google Scholar
• de Leon J, Susce MT, Pan RM, et al. A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels. Pharmacopsychiatry. 2007;40(3):93–102.
   PubMed Web of Science ®Google Scholar
• Ereshefsky L. Pharmacokinetics and drug interactions: update for new antipsychotics. J Clin Psychiatry. 1996;57(11):12–25.
   PubMed Web of Science ®Google Scholar
• Mannens G, Huang ML, Meuldermans W, et al. Absorption, metabolism, and excretion of risperidone in humans. Drug Metab Dispos. 1993;21(6):1134–1141.
   PubMed Web of Science ®Google Scholar
• Yasui-Furukori N, Hidestrand M, Spina E, et al. Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab Dispos. 2001;29(10):1263–1268.
   PubMed Web of Science ®Google Scholar
• de Leon J. The effects of antiepileptic inducers in neuropsychopharmacology, a neglected issue. Part II: pharmacological issues and further understanding. Rev Psiquiatr Salud Ment. 2015;8(3):167–188.
   PubMed Web of Science ®Google Scholar
• Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. E J Clin Pharmacol. 2008;64(12):1147–1161.
   PubMed Web of Science ®Google Scholar
• Snoeck E, Van Peer A, Sack M, et al. Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. Psychopharmacology (Berl). 1995;122(3):223–239.
   PubMed Web of Science ®Google Scholar
• Heykants J, Huang ML, Mannens G, et al. The pharmacokinetics of risperidone in humans: a summary. J Clin Psychiatry. 1994;55(Suppl):13–17.
   PubMed Web of Science ®Google Scholar
• Huang ML, van Peer A, Woestenborghs R, et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther. 1993;54(3):257–268.
   PubMed Web of Science ®Google Scholar
• de Leon J, Bork J. Risperidone and cytochrome P450 3A. J Clin Psychiatry. 1997;58(10):450.
   PubMed Web of Science ®Google Scholar
• Bork JA, Rogers T, Wedlund PJ, et al. A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A. J Clin Psychiatry. 1999;60(7):469–476.
   PubMed Web of Science ®Google Scholar
• Spina E, Avenoso A, Facciolà G, et al. Plasma concentrations of risperidone and 9-hydroxyrisperidone: effect of comedication with carbamazepine or valproate. Ther Drug Monit. 2000;22(4):481–485.
   PubMed Web of Science ®Google Scholar
• Fang J, Bourin M, Baker GB. Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn Schmiedebergs Arch Pharmacol. 1999;359(2):147–151.
   PubMed Web of Science ®Google Scholar
• Yatham LN, Grossman F, Augustyns I, et al. Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial. Br J Psychiatry. 2003;182:141–147.
   PubMed Web of Science ®Google Scholar
• Spina E, Hiemke C, de Leon J. Assessing drug-drug interactions through therapeutic drug monitoring when administering oral second-generation antipsychotics. Expert Opin Drug Metab Toxicol. 2016;12(4):407–422.
   PubMed Web of Science ®Google Scholar
• Hefner G, Falter T, Bruns K, et al. Elevated risperidone serum concentrations during acute inflammation, two cases. Int J Psychiatry Med. 2015;50(3):335–344.
   PubMed Web of Science ®Google Scholar
• Hefner G, Shams ME, Unterecker S, et al. Inflammation and psychotropic drugs: the relationship between C-reactive protein and antipsychotic drug levels. Psychopharmacology (Berl). 2016;233(9):1695–1705.
   PubMed Web of Science ®Google Scholar
• de Leon J, Susce MT, Pan RM, et al. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry. 2005;66(1):15–27.
   PubMed Web of Science ®Google Scholar
• Feng Y, Pollock BG, Coley K, et al. Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study. Br J Clin Pharmacol. 2008;66(5):629–639.
   PubMed Web of Science ®Google Scholar
• Paulzen M, Haen E, Stegmann B, et al. Clinical response in a risperidone-medicated naturalistic sample: patients’ characteristics and dose-dependent pharmacokinetic patterns. Eur Arch Psychiatry Clin Neurosci. 2016 Oct 1. DOI:10.1007/s00406-016-0736-z
   PubMed Web of Science ®Google Scholar
• de Leon J, Susce MT, Johnson M, et al. DNA microarray technology in the clinical environment: the AmpliChip CYP450 test for CYP2D6 and CYP2C19 genotyping. CNS Spectr. 2009;14(1):19–34.
   PubMed Web of Science ®Google Scholar
• Simpson GM, Lindenmayer JP. Extrapyramidal symptoms in patients treated with risperidone. J Clin Psychopharmacol. 1997;17(3):194–201.
   PubMed Web of Science ®Google Scholar
• Regenthal R, Kunstler U, Hesse S, et al. D2 dopamine receptor occupancy, risperidone plasma level and extrapyramidal motor symptoms in previously drug-free schizophrenic patients. Int J Clin Pharmacol Ther. 2005;43(8):370–378.
   PubMed Web of Science ®Google Scholar
• Migliardi G, Spina E, D’Arrigo C, et al. Short- and long-term effects on prolactin of risperidone and olanzapine treatments in children and adolescents. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(8):1496–1501.
   PubMed Web of Science ®Google Scholar
• de Leon J, Sandson NB, Cozza KL. A preliminary attempt to personalize risperidone dosing using drug-drug interactions and genetics: part II. Psychosomatics. 2008;49(4):347–361.
   PubMed Web of Science ®Google Scholar
• Chue P. Risperidone long-acting injection. Expert Rev Neurother. 2003;3(4):435–446.
   PubMedGoogle Scholar
• Malik K, Singh I, Nagpal M, et al. Atrigel: a potential parenteral controlled drug delivery system. Der Pharmacia Sinica. 2010;1:74–81.
   Google Scholar
• Llaudó J, Anta L, Ayani I, et al. Phase I, open-label, randomized, parallel study to evaluate the pharmacokinetics, safety, and tolerability of one intramuscular injection of risperidone ISM at different dose strengths in patients with schizophrenia or schizoaffective disorder (PRISMA-1). Int Clin Psychopharmacol. 2016;31(6):323–331.
   PubMed Web of Science ®Google Scholar
• Kane JM, Eerdekens M, Lindenmayer JP, et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry. 2003;160(6):1125–1132.
   PubMed Web of Science ®Google Scholar
• Castberg I, Spigset O. Serum concentrations of risperidone and 9-hydroxyrisperidone after administration of the long-acting injectable form of risperidone: evidence from a routine therapeutic drug monitoring service. Ther Drug Monit. 2005;27(1):103–106.
   PubMed Web of Science ®Google Scholar
• Laffont CM, Gomeni R, Zheng B, et al. Population pharmacokinetic modeling and simulation to guide dose selection for RBP-7000, a new sustained-release formulation of risperidone. J Clin Pharmacol. 2014;55(1):93–103.
   PubMed Web of Science ®Google Scholar
• Anta L, Llaudó J, Ayani I, et al. Pharmacokinetics, safety, and tolerability of four 28-day cycle intramuscular injections for risperidone-ISM 75 mg in patients with schizophrenia: a phase-2 randomized study (PRISMA-2). Eur Psychiatry. 2016;33:S240–S241.
   Google Scholar
• Farré M, Martínez J, Cordero P, et al. A clinical trial to evaluate the pharmacokinetics, safety and tolerability of single doses of risperidone with the novel long-acting injectable technology ISM in healthy volunteers. Eur Arch Psychiatry Clin Neurosci. 2011;261:S57.
   Google Scholar
• Ereshefsky L, Mascarenas CA. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. J Clin Psychiatry. 2003;64(Suppl 16):18–23.
   PubMed Web of Science ®Google Scholar
• Eerdekens M, van Hove I, Remmerie B, et al. Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophr Res. 2004;70(1):91–100.
   PubMed Web of Science ®Google Scholar
• Gefvert O, Eriksson B, Persson P, et al. Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. Int J Neuropsychopharmacol. 2005;8(1):27–36.
   PubMed Web of Science ®Google Scholar
• Nesvåg R, Tanum L. Therapeutic drug monitoring of patients on risperidone depot. Nord J Psychiatry. 2005;59(1):51–55.
   PubMed Web of Science ®Google Scholar
• Nesvåg R, Hendset M, Refsum H, et al. Serum concentrations of risperidone and 9-OH risperidone following intramuscular injection of long-acting risperidone compared with oral risperidone medication. Acta Psychiatr Scand. 2006;114(1):21–26.
   PubMed Web of Science ®Google Scholar
• Remington G, Mamo D, Labelle A, et al. A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. Am J Psychiatry. 2006;163(3):396–401.
   PubMed Web of Science ®Google Scholar
• Bai YM, Ting Chen T, Chen JY, et al. Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective, single-blind pharmacokinetic study. J Clin Psychiatry. 2007;68(8):1218–1225.
   PubMed Web of Science ®Google Scholar
• Gharabawi GM, Gearhart NC, Lasser RA, et al. Maintenance therapy with once-month administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing interval. Ann Gen Psychiatry. 2007;6:3.
   PubMedGoogle Scholar
• Uchida H, Mamo DC, Kapur S, et al. Monthly administration of long-acting injectable risperidone and striatal dopamine D2 receptor occupancy for the management of schizophrenia. J Clin Psychiatry. 2008;69(8):1281–1286.
   PubMed Web of Science ®Google Scholar
• Hendset M, Molden E, Refsum H, et al. Impact of CYP2D6 genotype on steady-state serum concentrations of risperidone and 9-hydroxyrisperidone in patients using long-acting injectable risperidone. J Clin Psychopharmacol. 2009;29(6):537–541.
   PubMed Web of Science ®Google Scholar
• Thyssen A, Rusch S, Herben V, et al. Risperidone long-acting injection: pharmacokinetics following administration in deltoid versus gluteal muscle in schizophrenic patients. J Clin Pharmacol. 2010;50(9):1011–1021.
   PubMed Web of Science ®Google Scholar
• Volonteri LS, Cerveri G, de Gaspari IF, et al. Long-acting injectable risperidone and metabolic ratio: a possible index of clinical outcome in treatment-resistant schizophrenic patients. Psychopharmacology (Berl). 2010;210(4):489–497.
   PubMed Web of Science ®Google Scholar
• Bowskill SV, Handley SA, Fisher DS, et al. Risperidone and total 9-hydroxyrisperidone in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 2002-2010. Ther Drug Monit. 2012;34(3):349–355.
   PubMed Web of Science ®Google Scholar
• Ikai S, Remington G, Suzuki T, et al. A cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: implications for dopamine D2 receptor occupancy during maintenance treatment in schizophrenia. J Clin Psychiatry. 2012;73(8):1147–1152.
   PubMed Web of Science ®Google Scholar
• Choong E, Polari A, Kamdem RH, et al. Pharmacogenetic study on risperidone long-acting injection: influence of cytochrome P450 2D6 and pregnane X receptor on risperidone exposure and drug-induced side-effects. J Clin Psychopharmacol. 2013;33(3):289–298.
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Lindenmayer JP, Kwentus J, et al. A six month randomized controlled trial of long acting injectable risperidone 50 and 100mg in treatment resistant schizophrenia. Schizophr Res. 2014;154(1–3):14–22.
   PubMed Web of Science ®Google Scholar
• Green AI, Brunette MF, Dawson R, et al. Long-acting injectable vs oral risperidone for schizophrenia and co-occurring alcohol use disorder: a randomized trial. J Clin Psychiatry. 2015;76(10):1359–1365.
   PubMed Web of Science ®Google Scholar
• Ganoci L, Lovrić M, Živković M, et al. The role of CYP2D6, CYP3A4/5, and ABCB1 polymorphisms in patients using long-acting injectable risperidone. Clin Ther. 2016;38(10S):e10–e11.
   Google Scholar
• Ikai S, Suzuki T, Mimura M, et al. Plasma levels and estimated dopamine D(2) receptor occupancy of long-acting injectable risperidone during maintenance treatment of schizophrenia: a 3-year follow-up study. Psychopharmacology (Berl). 2016;233(23–24):4003–4010.
   PubMed Web of Science ®Google Scholar
• Gomeni R, Heidbreder C, Fudala PJ, et al. A model-based approach to characterize the population pharmacokinetics and the relationship between the pharmacokinetic and safety profiles of RBP-7000, a new, long-acting, sustained-released formulation of risperidone. J Clin Pharmacol. 2013;53(10):1010–1019.
   PubMed Web of Science ®Google Scholar
• Laffont CM, Gomeni R, Zheng B, et al. Population pharmacokinetics and prediction of dopamine D2 receptor occupancy after multiple doses of RBP-7000, a new sustained-release formulation of risperidone, in schizophrenia patients on stable oral risperidone treatment. Clin Pharmacokinet. 2014b;53(6):533–543.
   PubMed Web of Science ®Google Scholar
• Isitt JJ, Nadipelli VR, Kouassi A, et al. Health-related quality of life in acute schizophrenia patients treated with RBP-7000 once monthly risperidone: an 8-week, randomized, double-blind, placebo-controlled, multicenter phase 3 study. Schizophr Res. 2016;174(1–3):126–131.
   PubMed Web of Science ®Google Scholar
• Nasser AF, Henderson DC, Fava M, et al. Efficacy, safety, and tolerability of RBP-7000 once-monthly risperidone for the treatment of acute schizophrenia: an 8-week, randomized, double-blind, placebo-controlled, multicenter phase 3 study. J Clin Psychopharmacol. 2016;36(2):130–140.
   PubMed Web of Science ®Google Scholar
• Ivaturi V, Gopalakrishnan M, Gobburu JV, et al. Exposure-response analysis after subcutaneous administration of RBP-7000, an once-a-month long-acting Atrigel formulation of risperidone. Br J Clin Pharmacol. 2017 Jan 30. Epub ahead of print. DOI:10.1111/bcp.13246
   Web of Science ®Google Scholar
• Remmerie BM, Sips LL, de Vries R, et al. Validated method for the determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;783(2):461–472.
   PubMed Web of Science ®Google Scholar
• Flanagan RJ, Harvey EJ, Spencer EP. HPLC of basic drugs on microparticulate strong cation-exchange materials. Forensic Sci Int. 2001;121:97–102.
   PubMed Web of Science ®Google Scholar
• Diaz FJ, Yeh HW, de Leon J. Role of statistical random-effects linear models in personalized medicine. Curr Pharmacogenomics Person Med. 2012;10(1):22–32.
   PubMedGoogle Scholar
• Rudberg I, Hendset M, Uthus LH, et al. Heterozygous mutation in CYP2C19 significantly increases the concentration/dose ratio of racemic citalopram and escitalopram (S-citalopram). Ther Drug Monit. 2006;28:102–105.
   PubMed Web of Science ®Google Scholar
• Shapiro S. Is meta-analysis a valid approach to the evaluation of small effects in observational studies? J Clin Epidemiol. 1997;50(3):223–229.
   PubMed Web of Science ®Google Scholar
• de Leon J. Evidence-based medicine versus personalized medicine: are they enemies? J Clin Psychopharmacol. 2012;32(2):153–164.
   PubMed Web of Science ®Google Scholar
• Elliott ES, Purvis TL, Nelson LA, et al. Inconsistency in risperidone long-acting injection steady-state plasma levels. J Clin Pharmacol. 2010;50(6):721–724.
   PubMed Web of Science ®Google Scholar
• Bader W, Greiner C, Wittmann M, et al. Clinical pharmacological comments are essential to supplement therapeutic drug monitoring (TDM) of schizophrenic patients treated with long-acting injectable risperidone. Biol Psychiatry. 2006;59:1S–264S.
   PubMed Web of Science ®Google Scholar
• Ereshefsky L, Saklad SR, Jann MW, et al. Future of depot neuroleptic therapy: pharmacokinetic and pharmacodynamic approaches. J Clin Psychiatry. 1984;45(5 Pt 2):50–59.
   PubMed Web of Science ®Google Scholar
• Sheehan JJ, Reilly KR, Fu DJ, et al. Comparison of the peak-to-trough fluctuation in plasma concentration of long-acting injectable antipsychotics and their oral equivalents. Innov Clin Neurosci. 2012;9(7–8):17–23.
   PubMedGoogle Scholar
• de Leon J. Training psychiatrist to think like pharmacologist, 2015. Available at http://inhn.org/home/courses/jose-de-leon-training-psychiatrists-to-think-like-pharmacologists.html [Last accessed 15 March 2017]
   Google Scholar
• Hendset M, Haslemo T, Rudberg I, et al. The complexity of active metabolites in therapeutic drug monitoring of psychotropic drugs. Pharmacopsychiatry. 2006;39(4):121–127.
   PubMed Web of Science ®Google Scholar